Tetrahydrobiopterin Deficiency Therapeutics
1. Sephience patent expiration
Treatment: Treatment of hyperphenylalaninemia (hpa) in adult and pediatric patients with sepiapterin-responsive phenylketonuria (pku) by administering sepiapterin; Method of treating hyperphenylalaninemia (hpa) ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11072614 | PTC | Polymorphs Of Sepiapterin And Salts Thereof |
Apr, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752154 | PTC | Pharmaceutical Compositions Comprising Sepiapterin And Uses Thereof |
Sep, 2038
(12 years from now) | |
| US12213982 | PTC | Pharmaceutical Compositions Comprising Sepiapterin And Uses Thereof |
Sep, 2038
(12 years from now) | |
| US12257252 | PTC | Compositions And Methods For Increasing Tetrahydrobiopterin Plasma Exposure |
Mar, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 28, 2030 |
Drugs and Companies using SEPIAPTERIN ingredient
NCE-1 date: 28 July, 2029
Market Authorisation Date: 28 July, 2025
Dosage: POWDER
More Information on Dosage
SEPHIENCE family patents
